anti-coagulants during hemodialysis
DESCRIPTION
Bancha Satirapoj , MD Division of Nephrology Department of Medicine Phramongkutklao Hospital and College of Medicine. Anti-coagulants during Hemodialysis. Dialysis and Thrombosis. Kidney disease Inflammation E ndothelial injury Expression and activity of procoagulant factors - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/1.jpg)
Anti-coagulants during
Hemodialysis
Bancha Satirapoj, MDDivision of Nephrology
Department of MedicinePhramongkutklao Hospital and College of
Medicine
![Page 2: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/2.jpg)
Dialysis and Thrombosis
Kidney disease Inflammation Endothelial injury Expression and activity of procoagulant factors
Dialysis process Needle, blood line, blood flow Platelet-platelet aggregation Platelet-erythrocyte aggregation Extrinsic and Intrinsic pathway activation
![Page 3: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/3.jpg)
Coagulation cascade
Inhibition of one molecule of factor Xa can inhibit the generation of 50 molecules of thrombin**
Extrinsic pathway
*Rosenberg RD, et al. N Engl J Med 1999;340:1555–64.
** Wessler S, et al. Thrombo Diath Haemorrh 1974;32:71–8.
Intrinsic pathway
1
50
Xa X
II
FibrinFibrinogen
Clot
Xa Va
PLCa2+
IIa
VIIIaCa2+
PL
IXa
![Page 4: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/4.jpg)
Extrinsic pathwayIntrinsic pathway
Dialyzer surfacePKK: HMWK↓KK
XII
XIIa
XI XIa
IX Ixa
X
Prothrombin
Fibrinogen Fibrin
Leukocyte activation
Tissuefactor
VIIa VII
XIII
XIIIa
VIIIa VIII
V Va
Xa
Thrombin
Citrate
Ca2+
Ca2+
Ca2+
Ca2+
DTI
LMWH
HEPARIN
Adapted from Shen JI, et al. Am J Kidney Dis. 2012; 60(3):473-486
Fibrin clot
![Page 5: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/5.jpg)
ANTICOAGULATION IN
HEMODIALYSIS PATIENTS
![Page 6: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/6.jpg)
Anticoagulation with RRT
Prevent clotting of the filter and reduction in membrane permeability
Adequate RRT Blood loss in the clotted filter
![Page 7: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/7.jpg)
Unfractionated Heparin
![Page 8: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/8.jpg)
Unfractionated Heparin Sulfate polysaccharide 45 saccharide units MW 10-16 kDa Most common anticoagulant
used for long-term hemodialysis
potential surface of heparin
![Page 9: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/9.jpg)
Heparin action
Stop the coagulation cascade and promoting anticoagulation
![Page 10: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/10.jpg)
UFH activity Half-life of UFH = 1 hour in patients with kidney failure
Half-life of UFH = 30 minutes in patients with normal kidney function
![Page 11: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/11.jpg)
Dosing Schedules for UFH for Anticoagulation During Long-term Hemodialysis
Loading Dose
Maintenance Infusion
Parameters for Adjustment
25-50 IU/kg 800-1,500 IU/hStop 30-60 min before end of treatment
If excessive bleeding or clotting occurs, adjust maintenance infusion by 500 IU/hIf excessive bleeding or clotting occurs, adjust loading dose by 500 IUIf clotting persists with loading dose >4,500 IU, addsecond bolus dose or add maintenance infusion by 500 IU/h
![Page 12: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/12.jpg)
Dosing Schedules for UFH for Anticoagulation During Long-term Hemodialysis
Loading Dose
Maintenance Infusion
Parameters for Adjustment
25-50 IU/kg 800-1,500 IU/hStop 30-60 min before end of treatment
If excessive bleeding or clotting occurs, adjust maintenance infusion by 500 IU/h
1000-2500 U
If excessive bleeding or clotting occurs, adjust loading dose by 500 IUIf clotting persists with loading dose >4,500 IU, addsecond bolus dose or add maintenance infusion by 500 IU/h
![Page 13: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/13.jpg)
Dosing Schedules for UFH for Anticoagulation During Long-term Hemodialysis
Loading Dose
Maintenance Infusion
Parameters for Adjustment
25-50 IU/kg 800-1,500 IU/hStop 30-60 min before end of treatment
If excessive bleeding or clotting occurs, adjust maintenance infusion by 500 IU/hIf excessive bleeding or clotting occurs, adjust loading dose by 500 IUIf clotting persists with loading dose >4,500 IU, addsecond bolus dose or add maintenance infusion by 500 IU/h
![Page 14: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/14.jpg)
Dosing Schedules for UFH for Anticoagulation During Long-term Hemodialysis
Loading Dose
Maintenance Infusion
Parameters for Adjustment
25-50 IU/kg 800-1,500 IU/hStop 30-60 min before end of treatment
If excessive bleeding or clotting occurs, adjust maintenance infusion by 500 IU/hIf excessive bleeding or clotting occurs, adjust loading dose by 500 IUIf clotting persists with loading dose >4,500 IU, addsecond bolus dose or add maintenance infusion by 500 IU/h
![Page 15: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/15.jpg)
Dosing Schedules for UFH for Anticoagulation During Long-term Hemodialysis
Loading Dose
Maintenance Infusion
Parameters for Adjustment
25-50 IU/kg 800-1,500 IU/hStop 30-60 min before end of treatment
If excessive bleeding or clotting occurs, adjust maintenance infusion by 500 IU/hIf excessive bleeding or clotting occurs, adjust loading dose by 500 IUIf clotting persists with loading dose >4,500 IU, addsecond bolus dose or add maintenance infusion by 500 IU/h
![Page 16: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/16.jpg)
Dosing Schedules for UFH for Anticoagulation During Long-term Hemodialysis
Loading Dose
Maintenance Infusion
Parameters for Adjustment
25-50 IU/kg 800-1,500 IU/hStop 30-60 min before end of treatment
If excessive bleeding or clotting occurs, adjust maintenance infusion by 500 IU/hIf excessive bleeding or clotting occurs, adjust loading dose by 500 IUIf clotting persists with loading dose >4,500 IU, addsecond bolus dose or add maintenance infusion by 500 IU/h
![Page 17: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/17.jpg)
Monitor Anti-coagulations
No routinely measure anticoagulation parameters Dialyzer clotting Prolonged bleeding following dialysis
Monitoring with the activated partial thromboplastin time (aPTT)
![Page 18: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/18.jpg)
Dialysis-specific factors: clotting Low blood flow High hematocrit High ultrafiltration rate Vascular access stenosis Poor needle placement
Anti-coagulant treatments
![Page 19: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/19.jpg)
STANDARD ANTICOAGULATION Heparin: pharmacodynamic
modeling Using an initial bolus followed by a constant fixed infusion of heparin to maintain an activated clotting time (ACT) of 200 to 250 seconds
Normal = 90 to 140 seconds
![Page 20: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/20.jpg)
Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses
Dialyzer reuse rates increased significantly over time in the treatment group but remained unchanged in the control group (P<0.003)
Ouseph R, Brier ME, Ward RA Am J Kidney Dis. 2000;35(1):89.Use of a heparin model can improve dialyzer reuse rates
treatment control05
1015202530
prepost
Num
ber o
f use
s
*
![Page 21: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/21.jpg)
UFH Bleeding
Heparin-induced thrombocytopenia
Hypertriglyceridemia Anaphylaxis Hyperkalemia Bone mineral disease
Decreased clotting of the dialysis circuit
Low cost Widely available Short half-life Reversible with
protamine
RisksBenefits
![Page 22: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/22.jpg)
Low molecular weight heparin
![Page 23: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/23.jpg)
Low molecular weight heparin
MW 4-5 kDa 18 saccharide units
LMWH inactivate factor XaLesser effect on thrombin (factor IIa)
![Page 24: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/24.jpg)
Low molecular weight heparin
![Page 25: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/25.jpg)
LMWH VS HEPARIN More specific binding action
>UFH Easier to dose by weight Single prefilled syringe injection Increased half-life 2-4 hr Prefer IV > SC
No agents for reverse its effects
![Page 26: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/26.jpg)
LMWH for Anticoagulation During Long-term Hemodialysis
LMWH MW(kDa)
Anti-Xa: anti-IIa
ratio
HF(hr)
Dose Dose in High risk of
bleeding
Enoxaparin
4,500 3.9 13.9 0.7 mg/kg 0.5 mg/kg
Nadroparin
4,300 3.3 2.5-3.5
BW <50 kg-0.3 mL (2,850 IU)BW 50–69 kg- 0.4 mL (3,800 IU) BW ≥70 kg-0.6 mL (5700 IU)
35 IU/kg
Tinzaparin
6,500 1.6 2.3 2,500 IU 2,000 IU
Dalteparin
6,000 2.5 2.2 5,000 IU 40-50 IU/kg2,500 IU
![Page 27: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/27.jpg)
LMWH for Anticoagulation During Long-term Hemodialysis
LMWH MW(kDa)
Anti-Xa: anti-IIa
ratio
HF(hr)
Dose Dose in High risk of
bleeding
Enoxaparin
4,500 3.9 13.9 0.7 mg/kg 0.5 mg/kg
Nadroparin
4,300 3.3 2.5-3.5
BW <50 kg-0.3 mL (2,850 IU)BW 50–69 kg- 0.4 mL (3,800 IU) BW ≥70 kg-0.6 mL (5700 IU)
35 IU/kg
Tinzaparin
6,500 1.6 2.3 2,500 IU 2,000 IU
Dalteparin
6,000 2.5 2.2 5,000 IU 40-50 IU/kg2,500 IU
![Page 28: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/28.jpg)
Monitor anticoagulations No routinely measure anticoagulation
parameters Dialyzer clotting Prolonged bleeding following dialysis
Monitoring with the activated partial thromboplastin time (aPTT) is not accurate
Measurement of anti-factor Xa levels keep 0.4-0.6 IU/mL or high risk bleeding 0.2-0.4 IU/mL
![Page 29: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/29.jpg)
Efficacy and safety
![Page 30: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/30.jpg)
1 2 3 4 5_7 8_100
1020304050607080
heparinclexane
Comparison of LMWH (enoxaparin) and standard heparin for HD anticoagulation 36 chronic HD pts Randomly assigned to enoxaparin (1 MKD) or
standard heparin, followed for 12 wks
Saltissi D, et al. Nephrol Dial Transplant 1999;14:2698-703.Grade
* *+
**** + +
Freq
uenc
y of
clo
t for
mat
ion
(%) Single-dose protocol of enoxaparin is an
effective and very convenient alternative to sodium heparin
![Page 31: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/31.jpg)
Meta-analysis: LMWH VS HEPARINBleeding: vascular access compression time
Lim W, et al. J Am Soc Nephrol 2004;15:3192-206.
LMWH and unfractionated heparin are similarly safe in preventing
extracorporeal circuit thrombosis
![Page 32: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/32.jpg)
Meta-analysis: LMWH VS HEPARINExtracorporeal circuit thrombosis
Lim W, et al. J Am Soc Nephrol 2004;15:3192-206.
LMWH and unfractionated heparin are similarly effective in preventing
extracorporeal circuit thrombosis
![Page 33: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/33.jpg)
Adverse effects
![Page 34: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/34.jpg)
Adverse effects: LMWH VS HEPARIN
Thrombocytopenia Osteoporosis Hyperkalemia Hyperlipidemia
![Page 35: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/35.jpg)
HEPARIN-INDUCED THROMBOCYTOPENIA IN HEMODIALYSIS Frequency of HIT is suggested to
be 8.1% of patients exposed to heparin
Significantly lower (1.8%) in patients exposed to LMWH
Syed S, Nat Rev Nephrol 2009;5:501-11.
![Page 36: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/36.jpg)
HEPARIN-INDUCED THROMBOCYTOPENIA Type I HIT
Heparin binds, activates, and depletes platelets.
Typically occurs within the first 4 days of starting heparin therapy
Mild thrombocytopenia with average 100,000/mm3
Resolves with time
Heparin therapy does not need to be stopped
![Page 37: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/37.jpg)
HEPARIN-INDUCED THROMBOCYTOPENIA Type II HIT
Usually occurs 5-12 day
Heparin binds to platelets, releasing platelet factor 4 (PF4)
More platelet aggregation
Paradoxical thrombus formation with limb-threatening ischemia
![Page 38: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/38.jpg)
HEPARIN-INDUCED THROMBOCYTOPENIA
Extensive cross-reactivity (>90 percent) between the LMWH and standard heparin in terms of antibody recognition
![Page 39: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/39.jpg)
HEPARIN-INDUCED THROMBOCYTOPENIA
No heparin hemodialysisRegional citrate hemodialysis
Change to peritoneal dialysis
Other anti-coagulants
![Page 40: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/40.jpg)
Heparin-induced thrombocytopenia (HIT)
In a patient with HIT All heparin must be stopped Using direct thrombin inhibitors
(argatroban) or Factor Xa inhibitors (danaparoid or fondaparinux) > other or no anticoagulation during RRT (1A)
In a patient with HIT who does not have severe liver failure Using argatroban rather than other
thrombin or Factor Xa inhibitors during RRT(2C)
KDIGO Clinical Practice Guideline for Acute Kidney Injury 2012
![Page 41: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/41.jpg)
Adverse effects: LMWH VS HEPARIN
Thrombocytopenia Osteoporosis Hyperkalemia Hyperlipidemia
![Page 42: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/42.jpg)
Effect of LMWH on bone metabolism in patients on maintenance hemodialysis 40 patients on stable hemodialysis using
unfractionated heparin (UFH) for more than 24 months
Tartrate-resistant acid phosphatase (TRACP) reflecting osteoclastic activity was elevated in 35% of patients.
Following LMWH treatment, TRACP was reduced by 13% (p<0.05)
Lai KN, et al. Int J Artif Organs 2001;24:447-55.
LMWH may partially alleviate osteoporosis associated with UFH administration in patients
on maintenance hemodialysis.
![Page 43: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/43.jpg)
Bone Mineral Disease
UFH is known to increase the risk of osteoporosis in pregnancy
![Page 44: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/44.jpg)
Adverse effects: LMWH VS HEPARIN
Thrombocytopenia Osteoporosis Hyperkalemia Hyperlipidemia
![Page 45: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/45.jpg)
Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of LMWH and unfractionated heparinComparison of unfractionated heparin (UH) and low
molecular weight heparin (LMWH) protocols
Hottelart C, et al. Artif Organs. 1998;22(7):614-617.
UH LMWH P value
Heparin dose per session
6,160 ± 1,350
2,220 ± 310
-
Plasma potassium
5.66 ± 0.83
5.15 ± 0.68
p < 0.05
Plasma aldosterone(pg/ml)
274 ± 205
435 ± 465
NS
Plasma aldo/RA (pg/ng/h)
112 ± 86
149 ± 123
p < 0.05
![Page 46: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/46.jpg)
Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of LMWH and unfractionated heparinComparison of unfractionated heparin (UH) and low
molecular weight heparin (LMWH) protocols
Hottelart C, et al. Artif Organs. 1998;22(7):614-617.
UH LMWH P value
Heparin dose per session
6,160 ± 1,350
2,220 ± 310
-
Plasma potassium
5.66 ± 0.83
5.15 ± 0.68
p < 0.05
Plasma aldosterone(pg/ml)
274 ± 205
435 ± 465
NS
Plasma aldo/RA (pg/ng/h)
112 ± 86
149 ± 123
p < 0.05
![Page 47: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/47.jpg)
Hyperkalemia Hypoaldosteronism with resultant
hyperkalemia is a known side effect of UFH
Predialysis potassium levels decreased from 5.66 mEq/L to 5.15 mEq/L when patients were given LMWH instead of UFH
Hottelart C, et al. Artif Organs. 1998;22(7):614-617.
![Page 48: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/48.jpg)
Adverse effects: LMWH VS HEPARIN
Thrombocytopenia Osteoporosis Hyperkalemia Hyperlipidemia
![Page 49: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/49.jpg)
Reduced lipid concentrations during four years of dialysis with LMWH
Deuber HJ, Schulz W. Kidney Int 1991;40:496-500.
-20 -10 0 10 20 30Time, months
500-400-300-200-100-
0-Trig
lyce
rides
, mg/
dL
Triglyceride levels were decreased when patients switched to LMWH and rebounded when they reverted to UFH
Heparin
LMWH
Heparin
![Page 50: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/50.jpg)
Reduced lipid concentrations during four years of dialysis with LMWH
Deuber HJ, Schulz W. Kidney Int 1991;40:496-500.
-20 -10 0 10 20 30Time, months
350-300-250-200-150-100-
50-0-Ch
oles
tero
l, m
g/dL
Cholesterol levels were decreased when patients switched to LMWH and rebounded when they reverted to UFH
Heparin
LMWH
Heparin
![Page 51: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/51.jpg)
Hypertriglyceridemia/VLDL and IDL
Depletion of lipoprotein lipase (LPL)
Bolus of heparin will release LPL into the free circulation
Ultimately depletes its stores, leading to a build-up of triglycerides
Cholesterol, VLDL, IDL and Triglyceride levels were decreased when patients switched to LMWH and rebounded when they reverted to UFH
Deuber HJ, Schulz W. Kidney Int 1991;40:496-500.
![Page 52: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/52.jpg)
Adverse effects: LMWH VS HEPARIN
Thrombocytopenia Osteoporosis Hyperkalemia Hyperlipidemia
![Page 53: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/53.jpg)
Prevent clotting with
High risks of bleedingPostoperative patients
Recent history of a bleeding event
![Page 54: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/54.jpg)
Prevent clotting with High risks of bleeding Normal saline flushing Regional anti-coagulation with
protamine reversal Regional Citrate anticoagulation Prostacyclin regional
anticoagulation
![Page 55: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/55.jpg)
Normal saline flushing No heparin hemodialysis for high risk of
bleeding Pretreating with 2000-5000 U of heparin with
0.9%NaCL 1 L BFR 250 to 500 mL/min Saline flushes 100-200 mL q 15-30 min into
the arterial limb Minimize hemoconcentration and fibrin
strands
Careful monitoring of the arterial and venous pressure alarms and saline volume
![Page 56: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/56.jpg)
Normal saline flushing
Risk for air embolismLow efficiency
![Page 57: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/57.jpg)
Regional anti-coagulation with protamine reversal Earliest method to reduce
hemodialysis associated bleeding Constant infusion of heparin into
the dialyzer inlet line Simultaneous constant infusion of
protamine prior to the blood returning to the patient
Protamine binds to heparin and eliminates its anticoagulant activity
![Page 58: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/58.jpg)
Regional anticoagulation with protamine reversal
![Page 59: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/59.jpg)
Regional anticoagulation with protamine reversal
Technical difficulties
Rebound bleeding 2-3 hours after dialysis as the RE system releases free heparin from the protamine-heparin complex back into circulation
![Page 60: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/60.jpg)
Regional citrate anticoagulation Reduced incidence of bleeding compared to
standard heparin protocols Trisodium citrate solution into the arterial
side of the dialyzer Fall free plasma calcium induced by binding
to citrate for the anticoagulant activity Citrate-calcium complex is removed across
the dialyzer Reversed by 5% CaCl2 infuse into the
venous return at a rate of 0.5 mL/min
Janssen MJ, et al Nephrol Dial Transplant. 1993;8(11):1228.
![Page 61: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/61.jpg)
Regional citrate anticoagulation
Other metabolic complication (acidosis, alkalosis, hypernatremia, hypocalcemia, hypercalcemia)
Requires strict protocol
![Page 62: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/62.jpg)
Frequent measurements of plasma electrolytes Hypocalcemia or hypercalcemia Hypernatremia (due to the hypertonic
sodium citrate solution) Metabolic alkalosis (due to
bicarbonate generated during the metabolism of citrate)
Regional citrate anticoagulation
Apsner R, et al. Am J Kidney Dis. 2005;45(3):557.
![Page 63: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/63.jpg)
KDIGO Clinical Practice Guideline for AKI 2012Recommendations: Anti-coagulation
Impaired coagulation ?
Intermittent RRT
Choose RRT Modality
Proceed withoutanticoagulation
Use anticoagulation adapted to this
condition
Underlying condition requiresSystemic
anticoagulation?
Proceed withoutanticoagulation
Proceed withoutanticoagulation
Regional CitrateAnticoagulation
Contraindicationto Citrate?Increased Bleeding Risk?
CRRT
Heparin Heparin
Increased Bleeding Risk?
Yes
Yes
Yes
No
No
No
KDIGO Clinical Practice Guideline for Acute Kidney Injury 2012
![Page 64: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/64.jpg)
New anticoagulant in dialysis
Cost Argatroban not safe in
hepatic impairment Hirudin and derivatives
have prolonged half-life No reversal agent Can be used in patients
with history of HITa
Cost Prolonged half-life No reversal agent Possibility of cross-
reaction with HIT antibodies
Can be used in patients with history of HITa
Direct thrombin inhibitors Heparinoids
Shen JI, et al. Am J Kidney Dis. 2012; 60(3):473-486
![Page 65: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/65.jpg)
Dialysis-specific factors: clotting Low blood flow High hematocrit High ultrafiltration rate Vascular access stenosis Poor needle placement
Anti-coagulant treatments
![Page 66: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/66.jpg)
Different anticoagulants in AKI patients
Anticoagulant Advantage Disadvantage
Heparin (unfractionated)
Wide availabilityLarge experienceShort half-lifeAntagonist availableMonitoring with routine tests(aPTT or ACT)Low costs
Narrow therapeutic index – risk of bleedingUnpredictable kinetics – monitoring requiredHITHeparin resistance
Adapted from KDIGO Clinical Practice Guideline for Acute Kidney Injury 2012
![Page 67: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/67.jpg)
Different anticoagulants in AKI patients
Anticoagulant Advantage Disadvantage
Heparin (unfractionated)
Wide availabilityLarge experienceShort half-lifeAntagonist availableMonitoring with routine tests(aPTT or ACT)Low costs
Narrow therapeutic index – risk of bleedingUnpredictable kinetics – monitoring requiredHITHeparin resistance
Low-molecular-weightheparin
More predictable kinetics– Weight-based dosing possibleMore reliable anticoagulant response– No monitoring requiredSingle predialysis dose may besufficient in IHDReduced risk of HIT
Risk of accumulation in kidney failureMonitoring requires non routine test (anti–Factor Xa)Different drugs not interchangeableIncomplete reversal by protamineIn most countries more expensive than unfractionated heparinAdapted from KDIGO Clinical Practice Guideline for Acute
Kidney Injury 2012
![Page 68: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/68.jpg)
Different anticoagulants in AKI patients
Anticoagulant Advantage Disadvantage
Saline flush No bleeding complication
Risk for air embolismLow efficiency
Adapted from KDIGO Clinical Practice Guideline for Acute Kidney Injury 2012
![Page 69: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/69.jpg)
Different anticoagulants in AKI patients
Anticoagulant Advantage Disadvantage
Saline flush No bleeding complication
Risk for air embolismLow efficiency
Citrate Strict regional anticoagulation– reduced bleeding risk
Risk of accidental overdose with potentially fatal consequencesInsufficient citrate metabolism in patients with reduced liver function and shock states resulting in accumulation with metabolic acidosis and hypocalcemiaOther metabolic complication (acidosis, alkalosis, hypernatremia, hypocalcemia, hypercalcemia)Increased complexityRequires strict protocol
Adapted from KDIGO Clinical Practice Guideline for Acute Kidney Injury 2012
![Page 70: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/70.jpg)
Thank you for your attention
Phramongkutklao Hospital and College of Medicine
![Page 71: Anti-coagulants during Hemodialysis](https://reader036.vdocuments.site/reader036/viewer/2022081801/56816523550346895dd7a586/html5/thumbnails/71.jpg)
Anticoagulation options for standard 4 h hemodialysis session